Cargando…
ADAM10-mediated release of heregulin confers resistance to trastuzumab by activating HER3
Receptor tyrosine kinases of the HER-family are involved in the development and progression of multiple epithelial tumors, and have consequently become widely used targets for new anti-cancer therapies. Trastuzumab, an antibody against HER2, has shown potent growth inhibitory effects on HER2 overexp...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4891117/ https://www.ncbi.nlm.nih.gov/pubmed/26863569 http://dx.doi.org/10.18632/oncotarget.7200 |